Entera Bio shares are up in recent trading, rebounding from an initial decline. Investors weighed the significant capital injection against dilution concerns from the large securities issuance.The stock moved upward even as the broader market faced headwinds, with the S&P 500 falling 0.9% and the health care sector gaining 0.2%. • Entera Bio stock is trading at elevated levels. What’s next for ENTX stock?What Is Driving ENTX Stock?Entera expects the financing to extend its cash runway into 2030 and fund EB613’s Phase 3 program through a planned FDA application.EB613 is Entera Bio’s investigational once-daily oral PTH(1-34) peptide tablet for osteoporosis, designed as a bone-building treatment.Entera will sell approximately 122.96 million ordinary shares and pre-funded warrants covering up to 11.84 million shares. The company priced the ordinary shares at $2.04 each and the warrants at $2.04 minus their nominal exercise price.Existing investor BVF Partners L.P. is leading the financing, alongside Longitude Capital, Vivo Capital, TCGX, RA Capital Management, Perceptive Advisors and other investors.After closing, BVF will also gain the right to designate two directors to Entera’s board, subject to applicable requirements.ENTX Technical Outlook: Momentum, RSI and Key LevelsWith Entera Bio’s stock price at $3.20, it is significantly above its 20-day simple moving average (SMA) of $2.07, indicating bullish momentum in the short term.The Relative Strength Index (RSI) reached 70.83, signaling overbought conditions and increasing the risk of a pullback if investors take profits.This overbought condition indicates that the stock may be stretched to the upside, and traders should watch for potential corrections.